CSIMarket Company Name, Ticker, Competitors, else..
 
Taysha Gene Therapies Inc   (NASDAQ: TSHA)
Other Ticker:  
 
 
Price: $1.5200 $-0.01 -0.654%
Day's High: $1.5501 Week Perf: -0.65 %
Day's Low: $ 1.46 30 Day Perf: -17.84 %
Volume (M): 2,221 52 Wk High: $ 4.32
Volume (M$): $ 3,376 52 Wk Avg: $2.31
Open: $1.51 52 Wk Low: $1.19



 Market Capitalization (Millions $) 407
 Shares Outstanding (Millions) 268
 Employees 112
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Taysha Gene Therapies Inc
Taysha Gene Therapies Inc is a clinical-stage gene therapy company focused on discovering, developing, and commercializing potential curative treatments for severe genetic disorders. Founded in 2020, the company utilizes its proprietary technology platform to develop transformative gene therapies for various neurological and lysosomal storage disorders. Taysha aims to address the underlying genetic cause of these disorders by delivering corrected genes or gene-modifying technologies to patients. The company is committed to advancing the field of gene therapy and improving the lives of patients suffering from debilitating genetic diseases.


   Company Address: 3000 Pegasus Park Drive Dallas 75247 TX
   Company Phone Number: 612-0000   Stock Exchange / Ticker: NASDAQ TSHA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BEAM      % 
CRBU      % 
DNA      % 
FDMT      % 
IMCR      % 
RGNX      % 
• View Complete Report
   



Shares

Taysha Gene Therapies Offers Inducement Stock Options Amid Talent Acquisition Strategy and Financial Recovery

Published Fri, Dec 6 2024 1:00 PM UTC

In a strategic move to bolster its workforce amid ongoing financial challenges, Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has announced an inducement grant for a new employee in conjunction with its efforts to attract top talent. The Dallas-based clinical-stage biotechnology company, which specializes in developing adeno-associated virus (AAV)-based gene therapies for sever...
Management Announcement

Taysha Gene Therapies Strives for Talent Amidst Financial Turmoil: A Path to Recovery or a Risky Gamble,

Published Fri, Nov 1 2024 8:31 PM UTC

Taysha Gene Therapies: A Balancing Act Between Talent Acquisition and Financial StrugglesIn the ever-evolving landscape of biotechnology, Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has recently taken center stage for a series of significant moves that highlight both ambition and concern. On November 1, 2024, the company?s Compensation Committee granted stock options amounti...
Financing Agreement

Taysha Gene Therapies Bolsters Workforce with Inducement Grants Despite Financial Challenges Under Nasdaq Rule 5635(c)(4),

Published Fri, Oct 4 2024 12:01 PM UTC

Taysha Gene Therapies, Inc. (NASDAQ: TSHA), a clinical-stage biotechnology company dedicated to advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), has made noteworthy movements on its executive compensation strategy as well as highlighted increasing financial challenges.On October 1, 2024, Tayshans C...
Management Announcement

Taysha Gene Therapies Grants Inducement Options to New Employees in Effort to Advance CNS Gene Therapies ? Share Price Sees Q3 Dip

Published Fri, Aug 2 2024 12:00 PM UTC



Taysha Gene Therapies, a prominent clinical-stage biotechnology company specializing in adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), has made a significant announcement today. On August 1, 2024, the Compensation Committee of Taysha s Board of Directors approved the issuance of options to purcha...
Management Announcement

Taysha Gene Therapies: Struggles in the Gene Therapy Market Amidst Inducement Grants and Financial Setbacks

Published Fri, Jul 5 2024 12:00 PM UTC



Taysha Gene Therapies, a clinical-stage biotech company specializing in gene therapies for severe monogenic diseases of the central nervous system, has recently made significant announcements regarding its operations. On July 3, 2024, the company granted four new employees options to purchase 484,000 shares of its common stock as an inducement for their recruitment...






Taysha Gene Therapies Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com